Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "A Phase 1b Trial Evaluating the Safety of Ribociclib, Tucatinib, & Trastuzumab for HER2+ mBC & Phase 2 Study of Preoperative Treatment With Ribociclib, Trastuzumab, Tucatinib +/- Fulvestrant vs. Docetaxel, Carboplatin, Trastuzumab, & Pertuzumab for HR+/-, HER2+ BC"

307 views
June 29, 2023
Comments 1
Login to view comments. Click here to Login